Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.8827
+0.1017 (13.02%)
At close: May 12, 2025, 4:00 PM
0.9000
+0.0173 (1.96%)
After-hours: May 12, 2025, 5:00 PM EDT
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $49.84 million as of May 12, 2025. Its market cap has decreased by -76.54% in one year.
Market Cap
49.84M
Enterprise Value
-31.32M
1-Year Change
-76.54%
Ranking
Category
Stock Price
$0.88
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $49.84M, a decrease of -93.82%. That is a compound annual growth rate of -45.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 9, 2025 | 44.10M | -37.16% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 659.45B |
| Johnson & Johnson | 371.06B |
| UnitedHealth Group | 345.29B |
| AbbVie | 326.55B |
| Novo Nordisk | 297.79B |
| Abbott Laboratories | 231.82B |
| Novartis AG | 214.71B |
| AstraZeneca | 211.14B |